Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer
Luca Cavallone, Adriana Aguilar-Mahecha, Josiane Lafleur, Susie Brousse, Mohammed Aldamry, Talia Roseshter, Cathy Lan, Najmeh Alirezaie, Eric Bareke, Jacek Majewski, Cristiano Ferrario, Saima Hassan, Federico Discepola, Carole Seguin, Catalin Mihalcioiu, Elizabeth A Marcus, André Robidoux, Josée-Anne Roy, Manuela Pelmus, Mark Basik, Luca Cavallone, Adriana Aguilar-Mahecha, Josiane Lafleur, Susie Brousse, Mohammed Aldamry, Talia Roseshter, Cathy Lan, Najmeh Alirezaie, Eric Bareke, Jacek Majewski, Cristiano Ferrario, Saima Hassan, Federico Discepola, Carole Seguin, Catalin Mihalcioiu, Elizabeth A Marcus, André Robidoux, Josée-Anne Roy, Manuela Pelmus, Mark Basik
Abstract
Response to neoadjuvant chemotherapy (NAC) in triple negative breast cancer (TNBC) is highly prognostic and determines whether adjuvant chemotherapy is needed if residual tumor is found at surgery. To evaluate the predictive and prognostic values of circulating tumor DNA (ctDNA) in this setting, we analyzed tumor and serial bloods from 26 TNBC patients collected prior, during, and after NAC. Individual digital droplet PCR assays were developed for 121 variants (average 5/patient) identified from tumor sequencing, enabling ctDNA detection in 96% of patients at baseline. Mutant allele frequency at baseline was associated with clinical characteristics. Levels drastically fell after one cycle of NAC, especially in patients whose tumors would go on to have a pathological complete response (pCR), but then rose significantly before surgery in patients with significant residual tumor at surgery (p = 0.0001). The detection of ctDNA early during treatment and also late at the end of NAC before surgery was strongly predictive of residual tumor at surgery, but its absence was less predictive of pCR, especially when only TP53 variants are considered. ctDNA detection at the end of neoadjuvant chemotherapy indicated significantly worse relapse-free survival (HR = 0.29 (95% CI 0.08-0.98), p = 0.046), and overall survival (HR = 0.27 95% CI 0.075-0.96), p = 0.043). Hence, individualized multi-variant ctDNA testing during and after NAC prior to surgery has prognostic and predictive value in early TNBC patients.
Conflict of interest statement
The authors declare no competing interests.
Figures
References
- Cortazar P, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164–172. doi: 10.1016/S0140-6736(13)62422-8.
- Symmans WF, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J. Clin. Oncol. 2007;25:4414–4422. doi: 10.1200/JCO.2007.10.6823.
- Masuda N, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N. Engl. J. Med. 2017;376:2147–2159. doi: 10.1056/NEJMoa1612645.
- Kuerer HM, et al. Nonoperative management for invasive breast cancer after neoadjuvant systemic therapy: conceptual basis and fundamental international feasibility clinical trials. Ann. Surg. Oncol. 2017;24:2855–2862. doi: 10.1245/s10434-017-5926-z.
- Merker JD, et al. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review. J. Clin. Oncol. 2018;36:1631–1641. doi: 10.1200/JCO.2017.76.8671.
- Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat. Rev. Clin. Oncol. 2017;14:531–548. doi: 10.1038/nrclinonc.2017.14.
- Beaver JA, et al. Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin. Cancer Res. 2014;20:2643–2650. doi: 10.1158/1078-0432.CCR-13-2933.
- Bettegowda C, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 2014;6:224ra24. doi: 10.1126/scitranslmed.3007094.
- Riva F, et al. Patient-specific circulating tumor DNA detection during neoadjuvant chemotherapy in triple-negative breast cancer. Clin. Chem. 2017;63:691–699. doi: 10.1373/clinchem.2016.262337.
- Garcia-Murillas I, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci. Transl. Med. 2015;7:302ra133. doi: 10.1126/scitranslmed.aab0021.
- Siravegna G, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med. 2015;21:827. doi: 10.1038/nm0715-827b.
- Siravegna G, et al. Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer. Clin. Cancer Res. 2019;25:3046–3053. doi: 10.1158/1078-0432.CCR-18-3389.
- Campone M, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. Eur. J. Cancer. 2018;103:147–154. doi: 10.1016/j.ejca.2018.08.002.
- Aguilar-Mahecha A, et al. The identification of challenges in tissue collection for biomarker studies: the Q-CROC-03 neoadjuvant breast cancer translational trial experience. Mod. Pathol. 2017;30:1567–1576. doi: 10.1038/modpathol.2017.82.
- Cavallone L, et al. A study of pre-analytical variables and optimization of extraction method for circulating tumor DNA measurements by digital droplet PCR. Cancer Epidemiol. Biomark. Prev. 2019;28:909–916. doi: 10.1158/1055-9965.EPI-18-0586.
- Dawson S-J, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 2013;368:1199–1209. doi: 10.1056/NEJMoa1213261.
- Fribbens C, et al. Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer. Ann. Oncol. 2018;29:145–153. doi: 10.1093/annonc/mdx483.
- Rothé F, et al. Circulating tumor DNA in HER2-amplified breast cancer: a translational research substudy of the NeoALTTO phase III trial. Clin. Cancer Res. 2019;25:3581–3588. doi: 10.1158/1078-0432.CCR-18-2521.
- Butler TM, Boniface CT, Johnson-Camacho K, et al. Circulating tumor DNA dynamics using patient-customized assays are associated with outcome in neoadjuvantly treated breast cancer. Cold Spring Harb. Mol. Case Stud. 2019;5(2):a003772. doi: 10.1101/mcs.a003772.
Source: PubMed